Clinical trials · Tampa, FL
Metastatic Castration-resistant Prostate Cancer clinical trials in Tampa
We’re tracking 27 recruiting metastatic castration-resistant prostate cancer studies with a site in or near Tampa — including Phase 1 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Tampa
- NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Sarasota, FloridaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Sarasota, FloridaAges 18 years+ - NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens near Tampa, FL
We’ll email you when one opens near Tampa, FL — at most once a week, no account needed, unsubscribe anytime.
Metastatic Castration-resistant Prostate Cancer trials in other cities
Where these studies are running near Tampa
Institutions with a site for the recruiting metastatic castration-resistant prostate cancer studies listed above.
- Florida Cancer Specialists & Research Institute · 3 studies
What taking part in a metastatic castration-resistant prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic castration-resistant prostate cancer studies in Florida.
Common questions
- Are there metastatic castration-resistant prostate cancer clinical trials near Tampa?
- Yes. We're currently tracking 27 recruiting metastatic castration-resistant prostate cancer studies with a site near Tampa, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic castration-resistant prostate cancer study near Tampa?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tampa to take part?
- Not necessarily. These studies have a site near Tampa, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic castration-resistant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic castration-resistant prostate cancer studies open near Tampa regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.